This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nuvilex Focused On Positioning Subsidiary, Medical Marijuana Sciences, Inc., To Be A Leading Medical Marijuana Entity By Developing Brain And Pancreatic Cancer Treatments

SILVER SPRING, Md., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, announced today that it is focused on positioning its subsidiary, Medical Marijuana Sciences, Inc., as a leader among entities in the medical marijuana field by virtue of its goal of using Cannabis constituents in the development of treatments for brain and pancreatic cancer.

Many companies in the medical marijuana arena are technology enterprises concerned with growth and distribution of marijuana or the production of numerous products containing marijuana or forms of its extracts. In contrast, Medical Marijuana Sciences, Inc. is utilizing a number of compounds found in marijuana plants and utilizing them to develop treatments for serious diseases. More specifically, using cannabinoids isolated from Cannabis sativa, Nuvilex's subsidiary will concentrate on the development of treatments for some of the deadliest forms of cancer that have historically shown that they are very difficult to treat with great success. Thus, this effort will initially involve pancreatic cancer and cancers of the brain, particularly glioblastomas. 

Nuvilex's COO, Dr. Gerald Crabtree commented "Nuvilex's "in-house" experience in drug development, particularly in the cancer area, coupled with the knowledge gleaned during the development of our pancreatic cancer treatment, serves as a strong foundation upon which Medical Marijuana Sciences can build treatments, using constituents of Cannabis, for deadly forms of cancer. By pursuing "hard targets" like cancers of the pancreas and brain, Medical Marijuana Sciences can position itself to become a leader among entities involved in the use of marijuana for medicinal purposes."

Nuvilex is a true biotechnology company by virtue of the development of a treatment for advanced, inoperable pancreatic cancer, through its subsidiary Austrianova Singapore (ASPL), involving the use of its proprietary cell encapsulation technology together with the well-known anticancer drug, ifosfamide. On the foundation of very promising results from two independent clinical trials by ASPL, wherein the pancreatic cancer treatment was found to double both the median survival time of patients as well as their one-year-survival rate, preparations are underway for a "late-phase" clinical study that if successful, will ultimately lead to approval by drug regulatory agencies for marketing of Nuvilex's pancreatic cancer treatment.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs